Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 15, 2026Clinical Cancer Research

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

FDFilippo Gustavo Dall’OlioWZWael ZrafiDVDamien Vasseur

Discussion

Loading...

Member takes

Overview

Randomized trial assesses ctDNA tumor fraction's predictive value for immunotherapy outcomes in aNSCLC, suggesting improved treatment guidance.

Key Points

  • The study aims to evaluate the predictive and prognostic value of ctDNA tumor fraction in advanced non-small cell lung cancer treatment.
  • Liquid biopsy assessments using next-generation sequencing of plasma cell-free DNA were conducted.
  • Data was collected from a nationwide NSCLC clinicogenomic database and an independent cohort for validation.
  • Correlation between ctDNA tumor fraction, metabolic tumor volume, and molecular profiles was analyzed.
  • In the CGDB Database (n=965), elevated ctDNA tumor fraction predicted worse outcomes on immune checkpoint blockers (HR 0.58 [0.41-0.82], p=0.002).
  • A tumor fraction ≥5% was identified as predictive of benefit from combined immunotherapy and chemotherapy.
  • In 283 patients, ctDNA tumor fraction showed a significant correlation with metabolic tumor volume (rho=0.46, p<0.001).

Cite This Study

Dall’Olio et al. (2026) studied this question.

synapsesocial.com/papers/6a57248e88b21df875480dcfhttps://doi.org/10.1158/1078-0432.ccr-25-3917
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 183P Comprehensive molecular profiling of tumor tissue and liquid biopsy in NSCLC patients treated with immune-checkpoint inhibitors2026
  2. 2The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis2026
  3. 3Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers2025
  4. 4Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers2025
  5. 5Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis2026